{"links":{"html":"https://www.erudio.com/reports/mars2-nct02040272","json":"https://www.erudio.com/reports/mars2-nct02040272.json","markdown":"https://www.erudio.com/reports/mars2-nct02040272.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"mars2-02040272"}},"request":"https://www.erudio.com/contact?report=mars2-02040272"},"offer":{"cited_commentary_sources":131,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a licence key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, to join with NPI-keyed systems such as a CRM. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":114,"optional":true,"price_per_verified_person_usd":15,"price_usd":1710,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One licence key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"mars2-nct02040272"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the licence key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=mars2-02040272","people":"Tom and Audun, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/mars2-nct02040272","renewal":"Subscriptions are prepaid and do not renew automatically.","terms":"https://www.erudio.com/terms"},"size":"deep","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-08T06:14:35.349644Z","notify_subscribers":false,"status":"corrected","summary":"A shared account card linked to one physician was removed; duplicate cards for the same person were combined"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":26,"coverage":"discussed","id":"A1","source_count":17,"title":"Routine, experimental and exceptional use of cytoreductive surgery"},{"claim_count":22,"coverage":"discussed","id":"A2","source_count":7,"title":"Resectability labels, systemic-treatment access and specialist referral"},{"claim_count":44,"coverage":"discussed","id":"A3","source_count":13,"title":"Histology, early-stage selection, fitness and proposed biomarkers"},{"claim_count":64,"coverage":"discussed","id":"A4","source_count":8,"title":"Imaging, invasive staging and tissue acquisition"},{"claim_count":39,"coverage":"discussed","id":"A5","source_count":9,"title":"Chemotherapy sequence, completion and subsequent treatment"},{"claim_count":48,"coverage":"discussed","id":"A6","source_count":12,"title":"Operative extent, quality assurance, mortality and oversight"},{"claim_count":28,"coverage":"discussed","id":"A7","source_count":17,"title":"Survival estimands, late curve crossing and harm terminology"},{"claim_count":44,"coverage":"discussed","id":"A8","source_count":13,"title":"Quality of life, costs, meaningful benefit and patient choice"},{"claim_count":38,"coverage":"discussed","id":"A9","source_count":16,"title":"Systemic alternatives and conditions for deferral or treatment holds"},{"claim_count":30,"coverage":"discussed","id":"A10","source_count":6,"title":"Radiotherapy, surveillance and multimodality sequencing"},{"claim_count":24,"coverage":"discussed","id":"A11","source_count":4,"title":"Intraoperative adjuncts and less-radical local approaches"},{"claim_count":54,"coverage":"discussed","id":"A12","source_count":9,"title":"Regional implementation and evidence-generation capacity"},{"claim_count":69,"coverage":"discussed","id":"A13","source_count":27,"title":"Randomized evidence, recruitment equipoise and cross-specialty debate"}],"counts":{"cited_sources":134,"claims_by_expression_type":{"comparison":115,"experience":91,"interpretation":228,"opinion":217,"primary_context":14,"question":163,"restatement":159,"uncertainty":69,"unspecified":38},"claims_by_kind":{"attributed_opinion":140,"counterview":25,"interpretation":71,"limitation":38,"protocol_statement":1,"source_observation":819},"evidence_units":751,"findings":12,"people_cited":98,"people_identity_verified":114,"people_total":141,"screened_sources":165,"verified_claims":1094},"depth":"rich","depth_rule":"thin if verified claims <30, findings <5, or cited sources <10; rich if verified claims >=100, findings >=8, and cited sources >=30; otherwise standard","findings_index":[{"id":"F1","title":"The central dispute is whether selected surgery can continue outside research—not whether surgery should remain routine"},{"id":"F2","title":"Changing the surgical decision can change drug access, referral, staging and diagnostic behavior"},{"id":"F3","title":"Early-stage epithelioid selection is a proposed exception, not a demonstrated rescue of surgery"},{"id":"F4","title":"Systemic-treatment delivery is debated as both a competing explanation and a consequence of surgery"},{"id":"F5","title":"Expertise arguments intersect with operative extent, diaphragm loss and recovery—not just center volume"},{"id":"F6","title":"Survival language and crossing-curve analysis are genuine points of disagreement"},{"id":"F7","title":"Quality time, costs and informed choice matter alongside survival—and patient preference does not compel an operation"},{"id":"F8","title":"Systemic treatment is a favored alternative, but histology, toxicity and conditions for holding treatment remain important"},{"id":"F9","title":"Radiotherapy is raised as a next step, but safety, treatment setting and appropriate observation limit the enthusiasm"},{"id":"F10","title":"Intraoperative adjuncts expose a distinct disagreement about benefit, renal harm and unproven less-radical approaches"},{"id":"F11","title":"Global implementation depends on diagnostic concentration, specialist capacity and the feasibility of generating local evidence"},{"id":"F12","title":"Praise for randomized evidence coexists with concern about bias, recruitment communication and the treatment of dissent"}],"medical_affairs_question":"What evidence threshold do clinicians require before offering selected surgery outside a trial, and how do they distinguish an exception from routine practice?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Routine surgery is challenged; the rules for exceptions remain contested"},{"id":"section-2","level":2,"title":"Resectability and referral affect more than the operation"},{"id":"section-3","level":2,"title":"Selected-patient benefit remains an evidentiary question"},{"id":"section-4","level":2,"title":"Treatment delivery: confounding concern or surgical-pathway burden?"},{"id":"section-5","level":2,"title":"Expertise, operative extent and mortality must be assessed separately"},{"id":"section-6","level":2,"title":"Survival interpretation includes substantive statistical dissent"},{"id":"section-7","level":2,"title":"Quality of life, costs and consent are central to the choice"},{"id":"section-8","level":2,"title":"Systemic alternatives need their own qualifications"},{"id":"section-9","level":2,"title":"Radiotherapy enthusiasm is limited by safety and the option to observe"},{"id":"section-10","level":2,"title":"Adjuncts and less-radical options have a separate evidence debate"},{"id":"section-11","level":2,"title":"Geography changes feasibility, not automatically the direction of benefit"},{"id":"section-12","level":2,"title":"Evidence standards and the fairness of appraisal remain part of the conversation"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, na"},"identity":{"accepted_at":"2026-10-08T06:14:35.349644Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-07T22:54:07Z","record_hash":"8deb4700376fd2df7a0f5090c63c93d04c0da5cc347add63fe7406f0f9164f69","release_hash":"290b3332d75649e30eaf65b95ff0aa9a2bbf2fa29b20c6a08b2971a3aad890fe","report_id":"erudio-nct02040272","run_id":"128c645b-214b-4b2e-a507-b63567c84fad","schema_version":"5.0","slug":"mars2-02040272","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"MARS 2 frames clinicians’ central question: should lung-sparing surgery be added to chemotherapy for people with pleural mesothelioma, and in what circumstances? Discussion covers patient selection, staging and tissue diagnosis, operative extent and center expertise, survival analysis, chemotherapy sequencing and completion, and systemic or radiotherapy alternatives. Other topics include treatment deferral and holds, quality of life, informed choice, costs, specialist referral, drug access, regional applicability, trial design and safety oversight.","meta_description":"165 HCP sources screened · 1094 verified claims from 134 sources · 12 findings. Updated 2026-10-08.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-eea3eb985d138f6f0b70"],"id":"F4","paraphrase":"A podcast host asked whether differing use of postoperative chemotherapy could weaken the MARS 2 comparison, or whether its importance was limited relative to the operation itself.","source_channel":"podcast","source_date":"2024-05-01","title":"Systemic-treatment delivery is debated as both a competing explanation and a consequence of surgery"},{"cited_claim_ids":["claim-35b82b4872075c5337f1"],"id":"F5","paraphrase":"A podcast moderator asked whether the independent monitoring committee had assessed interim data and whether safety concerns warranted stopping the study earlier.","source_channel":"podcast","source_date":"2023-09-26","title":"Expertise arguments intersect with operative extent, diaphragm loss and recovery—not just center volume"}]},"publication":{"approved_at":"2026-10-07T22:54:07Z","approved_by":"Audun Utengen","corrections":[{"affected_ids":[],"date":"2026-10-09T02:03:00Z","summary":"internal identifiers removed from public text"},{"affected_ids":[],"date":"2026-10-08T20:30:00Z","summary":"A shared account card linked to one physician was removed; duplicate cards for the same person were combined"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"1.0","scope_and_limits":{"commentary_scope":{"basis":"Reviewed retained sources only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"held_out_finds":24,"retrieval_gaps":["commentary:coverage_scope:keyword matches to trial identifier and registry aliases; single-letter acronym variants require planned context in the same indexed chunk; unnamed references or other transcription variants may be absent","commentary:indexed_source_unreadable:youtube:video_id:4F_fu5qT_xU:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:DZtPh-1D3-E:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:GkOVbdiRlNY:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:SbIMhCvmZ2k:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:v_CQHo9gReU:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:scribe_unavailable:mcp:podcast:94f000: diarized re-transcription failed; quotes use the discovery transcript.","commentary:held_out:mcp:podcast:3b4c5e@20407:23459: a claim turns Liu's description of surgery or continued chemotherapy into a resectability-based allocation rule: still-resectable patients underwent surgery while others continued chemotherapy. mcp:podcast:3b4c5e@20407:23459 does not establish that patients who became unresectable constituted the chemotherapy comparison group.","commentary:held_out:mcp:podcast:9d29a8@36322:36417,mcp:podcast:9d29a8@659:1230,mcp:podcast:9d29a8@26839:28814,mcp:podcast:9d29a8@36062:36320: a claim establishes ongoing trial enrollment from a geography-only answer. mcp:podcast:9d29a8@36322:36417 says only 'So far, it's just been in California,' in response to mcp:podcast:9d29a8@36062:36320, while mcp:podcast:9d29a8@26839:28814 describes a clinical trial that is going to open. The supplied exchange does not resolve whether formal trial enrollment had begun.","commentary:held_out:mcp:podcast:d95a3d@8433:8597,mcp:podcast:d95a3d@8706:8866,mcp:podcast:d95a3d@6324:6471,mcp:podcast:d95a3d@9219:9369: a claim and a claim definitively assign Riess's staging and histology critiques to the original MARS trial. Although the host repeatedly keeps the discussion on the first MARS study, Riess subsequently acknowledges in mcp:podcast:d95a3d@9219:9369 that he was jumping ahead. The supplied exchange therefore leaves the precise study referent of these critiques unresolved.","commentary:held_out:mcp:podcast:e38cf3@58911:59995,mcp:podcast:e38cf3@1385:1865: a claim names Stephanie Shaw. The mcp:podcast:e38cf3 source-scoped participant metadata and handoff in mcp:podcast:e38cf3@1385:1865 identify Stephanie Saw, whereas the issued speaker decision and transcript label for mcp:podcast:e38cf3@58911:59995 use Stephanie Shaw. This spelling conflict is unresolved; the decision does not authorize choosing the conflicting name.","commentary:held_out:mcp:x_thread:1702526057419571244:a2a334ff-efd1-4981-9ec7-a03231875cd5@8971:9408,mcp:x_thread:1702526057419571244:a2a334ff-efd1-4981-9ec7-a03231875cd5@8523:8969: a claim resolves Naidoo's 'This will create inherent bias' specifically to differential immunotherapy receipt. mcp:x_thread:1702526057419571244:a2a334ff-efd1-4981-9ec7-a03231875cd5@8971:9408 does not identify that referent. The surrounding exchange discusses several differences, including disease burden, chemotherapy and additional therapies; mcp:x_thread:1702526057419571244:a2a334ff-efd1-4981-9ec7-a03231875cd5@8523:8969 separately raises immunotherapy receipt. The specific object of agreement in mcp:x_thread:1702526057419571244:a2a334ff-efd1-4981-9ec7-a03231875cd5@8971:9408 is not unambiguous.","commentary:held_out:mcp:x_thread:1702526057419571244:a2a334ff-efd1-4981-9ec7-a03231875cd5@19249:19541: a claim says Stiles accepted a point about patient selection as not changing the prior argument. mcp:x_thread:1702526057419571244:a2a334ff-efd1-4981-9ec7-a03231875cd5@19249:19541 says 'It doesn't change it' but does not identify that antecedent. Nearby supplied posts discuss Addeo's immunotherapy answer, randomized surgical evidence and Popat's patient-selection argument. The claim selects one object of agreement that the exchange leaves ambiguous.","commentary:held_out:mcp:podcast:7484f0@5969:8124: The supplied inventory retains only surgical resectability in a claim. It omits Fernando's connected eligibility and generalizability view: tissue confirmation, disease confined to one hemithorax assessed by CT alone, ECOG 0–1, no end-organ failure, and his contrast with the typically older mesothelioma patients he had seen. These passages are outside the supporting quotations of the supplied Fernando claims.","commentary:held_out:mcp:podcast:8788f6@18514:21134,mcp:podcast:8788f6@26356:29154,mcp:podcast:8788f6@29156:31765,mcp:podcast:8788f6@31767:34289,mcp:podcast:8788f6@34291:36854,mcp:podcast:8788f6@36856:39603,mcp:podcast:8788f6@66880:68942,mcp:podcast:8788f6@16004:18159,mcp:podcast:8788f6@18161:18512,mcp:podcast:8788f6@0:2194: a claim–a claim and a claim–a claim name Crispin Highley, but the transcript rendering conflicts with the source's own speaker metadata and the handoffs in mcp:podcast:8788f6@0:2194, mcp:podcast:8788f6@18161:18512 and mcp:podcast:8788f6@16004:18159, which identify Crispin Hiley. The issued transcript speaker label does not resolve that contradiction. The report's description of these as source-named Highley views therefore assigns an unresolved name to clinical commentary.","commentary:held_out:mcp:podcast:8788f6@14003:16002,mcp:podcast:8788f6@16004:18159,mcp:podcast:8788f6@2196:2874: a claim converts Tenconi's pre-result consideration of a possible negative MARS II result into an established negative MARS I result. The surrounding passage explicitly introduces two possible future outcomes and contrasts the negative branch with 'if it is positive instead.' a claim and a claim also lose the negative-result condition governing the eligibility and induction-chemotherapy criticisms.","commentary:held_out:pubmed:38760029@13433:18034: a claim renders the wife's uncertain account of a '75%, probably 85% or whatever, better chance' as a numerical chance of improved survival. The source does not resolve whether these percentages represent a probability, a relative improvement, or another estimate.","commentary:held_out:mcp:podcast:8788f6@56852:58104: The retained IPC symptom-support view in a claim is not accompanied by Tenconi's connected account of infection risk, risk from repeated manipulation, and the conditions for reducing drainage frequency or using patient-led drainage.","commentary:held_out:mcp:podcast:8788f6@40447:43361,mcp:podcast:8788f6@43363:46118,mcp:podcast:8788f6@46120:48866: The connected nonsurgical first-line discussion omits the unidentified speaker's preference for doublet immunotherapy, the quality-of-life rationale, the unresectable CheckMate 743 population and lack of power for subtype conclusions, and the speaker's adverse-event and management qualifications.","commentary:held_out:mcp:podcast:8788f6@43363:46118: The unidentified speaker's comparison of cisplatin and carboplatin survival, followed by a rhetorical challenge to using cisplatin, is absent from the retained commentary. This explains the choice of an explicitly discussed systemic alternative.","commentary:held_out:mcp:podcast:8788f6@43363:46118: The connected perioperative caution is missing: the speaker describes slightly inferior checkpoint-inhibitor PFS during the first seven months and says immunotherapy should not be used as induction before surgery because the guidelines recommend chemotherapy around surgery.","commentary:held_out:mcp:podcast:8788f6@62280:62429: Popat's categorical statement that PD-L1 testing has no role whatsoever in mesothelioma is absent. It is a distinct treatment-selection view in the same panel and differs in certainty from Forde's retained statement that predictive value is very unclear.","commentary:held_out:mcp:podcast:8788f6@64360:65010: The report retains uncertainty about NICE funding but omits Popat's contemporaneous statement that doublet immunotherapy was already obtainable through compassionate supply, his lack of knowledge about NHS funding negotiations, and his strong preference conditional on trial eligibility and drug suitability.","commentary:held_out:mcp:podcast:8788f6@60757:61458: The connected patient-support reply omits advice to report pain or lumps around a procedure site to the oncologist, together with the explicit absence of evidence proving that earlier treatment is better and the analogy to other fungating lesions.","commentary:held_out:mcp:x_thread:1716162371738091592:80cdf2e3-4174-4fec-b5d5-23265c590aba@26220:27099: Forde's general sequencing view—first-line immunotherapy followed by chemotherapy, or the reverse—and his acceptance of carboplatin are missing from the connected treatment-decision inventory.","commentary:held_out:mcp:x_thread:1716162371738091592:80cdf2e3-4174-4fec-b5d5-23265c590aba@44064:44908: Forde's explicit general view against maintenance pemetrexed in mesothelioma is absent from the same treatment-decision exchange. This is a distinct reason not to continue systemic treatment automatically.","commentary:held_out:mcp:x_thread:1716162371738091592:80cdf2e3-4174-4fec-b5d5-23265c590aba@50699:51554: Marmarelis's reply that she usually does not continue pemetrexed is absent, as is her consequential qualification that the relevant trial did not fully accrue and was not powered to answer the question definitively.","commentary:held_out:mcp:x_thread:1781643312643883515:f681de8e-36b9-4aa8-b5fc-1524d3f0687a@1163:1437: The connected HIT-Meso implementation discussion omits Shah's account of both NHS proton centers and satellite sites delivering non-proton components locally, including plans to open more satellites. This is access-mitigating context alongside the retained delivery and centralization constraints."],"source_count":165,"unreadable_unit_ids":[]},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","24 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.","5 further source limits are recorded in the machine-readable scope of this record.","The evidence describes reviewed commentary, not a representative survey of HCP opinion, guideline adoption or surgical utilization.","Multiple sources may repeat the same person, event or discussion; source counts must not be interpreted as independent clinician counts.","Some statements are reported opinions, patient recollections, institutional accounts or anecdotal experiences rather than direct clinician testimony or controlled evidence.","Uncertain speakers remain unnamed; adjacent named contributions do not establish who spoke a continuation.","Some accounts use inconsistent procedure names, endpoint descriptions or numerical wording. They are retained as commentary rather than silently corrected into trial facts.","Several subgroup and cross-study interpretations lack effect estimates, uncertainty intervals or appropriate nonsurgical comparisons in the cited passages.","Treatment-access, professional-context and practice descriptions are source- and time-specific, not current global verification.","The recruitment publication did not interview over one-third of approached professionals and lacked consultation recordings from half the study sites.","Searches may have missed unnamed trial references or transcription variants, and five identified videos could not be reviewed.","One podcast's available transcript leaves some speaker identities uncertain; this limits attribution but does not justify assigning those views to rostered participants."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":22,"publication":3,"registry":0,"regulatory":0,"x_thread":102,"x_video":0,"youtube":7},"by_evidence_role":{"commentary":131,"context":2,"methods":1},"count":134,"evidence_window":{"end":"2026-09-12","start":"2023-02-10"},"retrieval_snapshot":"2026-10-08T04:04:08.336751Z","timeline":[{"count":1,"week":"2023-W06"},{"count":1,"week":"2023-W13"},{"count":1,"week":"2023-W23"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W36"},{"count":45,"week":"2023-W37"},{"count":6,"week":"2023-W38"},{"count":2,"week":"2023-W39"},{"count":1,"week":"2023-W40"},{"count":1,"week":"2023-W41"},{"count":3,"week":"2023-W42"},{"count":5,"week":"2023-W43"},{"count":1,"week":"2023-W44"},{"count":1,"week":"2023-W45"},{"count":2,"week":"2023-W46"},{"count":1,"week":"2023-W51"},{"count":2,"week":"2024-W08"},{"count":1,"week":"2024-W09"},{"count":1,"week":"2024-W10"},{"count":1,"week":"2024-W14"},{"count":7,"week":"2024-W16"},{"count":2,"week":"2024-W17"},{"count":1,"week":"2024-W18"},{"count":4,"week":"2024-W19"},{"count":3,"week":"2024-W20"},{"count":1,"week":"2024-W21"},{"count":2,"week":"2024-W22"},{"count":3,"week":"2024-W23"},{"count":2,"week":"2024-W25"},{"count":1,"week":"2024-W31"},{"count":2,"week":"2024-W37"},{"count":3,"week":"2024-W50"},{"count":1,"week":"2024-W51"},{"count":3,"week":"2025-W02"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W11"},{"count":2,"week":"2025-W12"},{"count":2,"week":"2025-W13"},{"count":2,"week":"2025-W14"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W38"},{"count":4,"week":"2025-W44"},{"count":1,"week":"2025-W51"},{"count":2,"week":"2026-W07"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W35"},{"count":2,"week":"2026-W37"}],"undated_sources":3},"quote_policies":[{"id":"clinicaltrials:NCT02040272:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02040272:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:31627746","quote_policy":"short_quote_link_out"},{"id":"pubmed:32873681","quote_policy":"short_quote_link_out"},{"id":"pubmed:38740044","quote_policy":"short_quote_link_out"},{"id":"pubmed:38760029","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:13e4c9","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:187200","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:3b4c5e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:4be08a","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:605b72","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:64e435","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7484f0","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8788f6","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:9091f3","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:94f000","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:99f037","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:9d29a8","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:9d3472","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b5cbed","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c81ba7","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ca59ea","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:d1efac","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:d95a3d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:db8c27","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e38cf3","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f833cc","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:fc4165","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1456941573900472322:7548ec27-9914-464d-b4bb-0c4a921257d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1624058281319710722:b7ec074d-1180-4575-98ff-3f8608f16fd8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1641363325526106113:5f09cfbe-1ce0-4658-babc-9c4456cd0e48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1673310191964635138:a98d87d1-d4a8-4353-bdec-42caab76d0d3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1699450185708196225:a5739110-376d-49b4-8901-d5aeab1e096f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701002326767784206:adc570f0-3729-453a-b702-9713b57bca14","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701038704620413191:fcc8fd28-c379-4809-9012-9a0193d4b91f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701046160943874374:babc4ac5-2b3c-4593-a789-47ef1d6c57b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701046606894899364:c44ffb2a-8282-4549-9cac-5d592f83b5eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701046719952368024:bc1f9fd2-9f21-4260-8923-e70225339baf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701046858200776880:72bb9a81-c796-4c93-814b-b0561ef347dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701046858968424503:8623531e-a4e5-41e1-94c6-b49d5df60fa5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701047391393398975:4d771eb4-fea0-44d2-9b39-8dd5bd088718","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701047494212493589:1e437f43-d7c4-47c8-b375-d7d66af50ce6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701047630447706375:93e9398a-85e9-4b7d-b13b-887824f7ae7f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701047663729537239:f7661766-013c-48c8-aec0-91572aff7b3c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701047822173491311:54c55579-960a-46a1-b636-ce4edd2b0569","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701047889139826963:67ccdaa8-d383-4d7a-a8fd-1216f4351e02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701048027711201702:59d4b0d8-3754-4ac3-a2cf-11beeba85aad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701048092487737670:d38f6978-883b-4831-8609-0d46e2dba621","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701048242585362840:f0cc6e06-deb0-45c6-be34-02cbb25eb0f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701048443484156410:7624d275-e2de-40bd-b08f-b8d5fcf600ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701048473393746133:6d551364-b931-4f06-9479-aadb081208af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701048731075047888:f6e7d7aa-64bb-4278-a354-005d679df3e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701049504898986047:d075df51-e693-4a16-865e-1bbb8a4fb63c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701049699200032826:0a2516ce-f8eb-42b4-a921-f4913740ae09","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701050940185526611:3f919b5b-41fe-4207-87d3-3c829f4d71b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701051400740868183:a4005f6e-2f28-4de8-9b40-9e07b7fb6c5c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701052664136769678:4a566998-269b-417c-8e87-73a11bf774d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701052998372495765:f42624ad-cf52-4ba8-a6fd-c1e4498ed209","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701053034283901337:d7335882-e1bb-4758-baf7-c7d4d2ba75c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701054157388742676:3d5340b8-439d-4387-926d-abb3d2acd0b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701054696037999032:c157a4e2-9be1-4dea-8ee8-cabc2bc20598","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701055005984469037:672184d9-637d-44cd-bdd2-1335d6f5b275","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701056439761219644:e708a54e-2f48-4c4b-b79a-27461ce41df5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701057124271317483:12528030-c3ee-4f7e-8ae7-fba3e98143b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701082894301790235:941be9f0-8cc7-4815-af78-0f29e5586597","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701084604890026194:1b3c07fd-9c65-4ef3-9a4a-663d5080f5f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701103548551868550:dbb6e942-65d5-4ed0-80f9-df1bec33a4b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701166863349100767:1fde5e39-df55-44a7-ac04-ebd7e0781207","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701212810871537716:e119de54-4822-4ec1-8775-a7d7bbd92249","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701218155887010069:49f9a238-1cde-49d6-a3fa-6782d8d43c32","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701228325065179329:d37c39a5-e517-40da-b5f9-180c069cf1f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701349966201893118:0148f8a3-75bc-4e6a-b1d5-ea17bec05afe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701424746011693091:2063a22c-3753-4cd9-940b-454cd56c1462","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701628994565685501:8c0cec50-4d98-47e0-9c25-530f257ea6a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702526057419571244:a2a334ff-efd1-4981-9ec7-a03231875cd5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702542174230094242:57ccf61f-e3f2-4d2d-ba80-2fe7de67a9a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702542339422765166:87e9a7bc-9710-41b8-bc28-d2a1c24157a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702620664316711327:76b0800f-6959-4ab3-8837-eb62680f5cd0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702655601027711339:61977e0c-a331-4295-b1f0-fbe410243a4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702769879936377042:4ddc16ba-9320-4e6c-bdb7-f7c735fb43a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1703036498654756893:c8bef134-bfd6-415b-a161-ceeb9e8c8865","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1704474290693820473:c470a085-fa15-497d-b35d-ce9760c20161","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1704994661188747492:a5a7baba-ce90-4e6a-a368-4775a83686cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1705241030411375000:a87d821d-782a-445c-b9e6-1eae147c1f3e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1705299182108672284:38802ef7-4ff8-41bd-9c4b-2302768a2c01","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1709350668496957611:90986786-7c22-424b-9539-8db9c84120ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1710482392102707296:4ed6f924-8e63-4741-b595-592f5c974e28","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1710630629308612885:9566e4d6-f7ba-4b1b-8b03-93547772ff2b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1714604453838385277:657ef839-c21b-4486-a8c1-15d39c0fa1f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716162371738091592:80cdf2e3-4174-4fec-b5d5-23265c590aba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716960738525241772:b9ca0474-4fad-48bc-85c6-66cc54e10284","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716968424742470100:d233f0dd-e6e3-4e4f-90cc-7c2df8f33f0c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1717674273295261849:6a2308b0-a662-41a8-a183-efd88224e58f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1723342681253056567:22005774-093f-4668-8f60-3bce9a389c85","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1723344886726857143:31662b8e-077c-4821-9f29-146b750a0249","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1726019947082686665:6d317007-c501-4d60-a351-18e2ad4ae2ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1726021232011952288:21ceb0c9-4db8-4e28-9136-34951dbe810d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1761102638492565766:dbe8f330-5d3e-4c07-9ffc-039a9a170485","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1761118653997879355:84e13f17-6cb7-4158-8b7c-9259ad3547e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1761122594139632078:043227ad-2e25-4af9-912e-e152035b425c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1766608214995390632:a590253d-7715-4af4-8ea9-3018e4c49174","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1771140677411197410:4b275313-d1f9-488b-a29f-6ae5d566f044","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1780948769783054582:137f12c1-9eec-4d5c-93c5-1ad610261392","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1780959294630068304:5864494a-4840-4941-baef-4fda9f0c11f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781357418552697322:075b7ce3-1a5e-4bb7-8d63-bacaa390f737","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781357647402344803:235ebd59-9008-4361-aae5-d8ce65af49e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781357877761892582:5db74090-9591-496b-bad8-fd065fbc8e35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781614967923343403:ccb45886-e538-4e32-9350-344325eea9d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781643312643883515:f681de8e-36b9-4aa8-b5fc-1524d3f0687a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1789684208744456614:fd1ecbce-f54b-48ed-bb2a-ca3914558594","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1789690405241430421:7374d36d-525e-41b1-972b-fa9535b35439","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1789707967178096714:1bf50108-c3cc-4656-9414-d777d124f89a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1789708662795034923:1ef0da52-4b65-4a04-8c45-6f0ca881e8b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1789748245901516807:b69d4fa9-b4a4-475a-92bb-5a3896cba3b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1789843653147660332:4ddd4a3f-dd41-44a9-bb34-21ef5c09218f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790997617796878793:a3730c97-b4c8-43c4-85a7-79c581b13e72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1791029969621049699:4f839feb-3ac9-4f5d-9689-aec7f4ffec74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1792183999164522893:7757f003-df91-436f-877f-adfd4823bcf1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1795064024763133970:fec3a401-e669-4d17-9d07-9fb6c9cd9654","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796029378922512745:654f7ca4-98c2-4afc-9d1c-4cd546c73794","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797623423994401014:a85d7c98-1241-46d1-ad3d-d91129e1cba3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797628017059258396:0aa27c50-0326-4284-b212-5e4a1e813ea8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797628493532213539:8bf593c0-fc05-4a08-af99-c32fa1f9c6eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1804096271344451827:dea5ecb8-7f97-4986-b229-27f70a214109","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1804111151485137142:ff6170f6-7f0f-4cb5-b82f-e1080ca78524","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834948438091305098:ec547245-7219-4bfe-a5e4-6166954078ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834950995211636742:d7db3916-61ba-41e7-9a3b-a87b98042fda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1852202788895469650:bfe97ddc-6cca-4b23-b885-2ba72d75ecff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865868278624555076:5db29e3b-a6db-4e8a-85d3-9e3abf174858","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866077017357062326:71381a5c-ffaa-42f4-973d-148b79d0549e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866079845765021912:a84312ff-ee92-4c33-ad2d-06207aefae18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866080545903370384:95f8dfc4-2b13-482d-ab29-63ca9fba0372","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866089723975938228:81c065e6-e33e-456d-9a21-3709312dcfce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1869352496222847172:08db8365-4dd5-4265-93c7-6337f396e014","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1877257178156773512:fbfa9e99-74ed-4a50-9663-40c4028cdec0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1877458344140583422:02f2eea9-1145-46be-85f9-9f74da8f8275","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1878082415538700750:2add5032-d2d6-4ac0-be42-f710dace0cfb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1879103782904315964:3d7f7e08-de66-4de1-88f1-99a874394deb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1883082524488040637:26118f42-ea88-4a70-9c1d-738a4ca5d564","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1898579120885293257:9456a137-2235-4349-ac7d-418ecb07aa84","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1899357119478125027:c5b8f693-f1b3-4273-b2b9-d69d0cea9a76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1901590968912249047:57338e5f-7970-45c0-909f-550cb96ad9e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1902323051389153562:f38cca9a-e1d1-4dfe-bb4c-919dc54303db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1903555031409807516:cc70271e-7ed5-4613-89de-fc4982745b65","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1905572781653180675:3564e52c-a55a-449c-b66e-f0667e0122d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1913859149005217992:42ef6f72-6844-40a4-9c93-29e770c984d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1939066163712885104:b886a0a2-a2bd-4e49-8903-a95eba3ec7ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964218009880342945:890a6255-c722-46e9-9a4d-8cb7e95fe204","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964221932288552989:6ef77bae-4c8e-439f-837d-7ad2513ccd56","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1968360885866610853:bfaed2ce-b2d8-4c59-b97d-25c6fbe3c5ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1974044939844501902:4c563ecc-c425-4ae7-846b-554e5723194f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979915108756156864:f8a9e278-c515-4c92-86dc-2e8013fcb833","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980373098034799054:84017076-9ed3-4d7f-8c9b-8242620c6972","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1982807044403958038:390c802b-baed-4649-8344-1cad9e47a70a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1982807177795342484:86371b6b-e01f-4259-a3ce-2957986e26d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1983049812107784228:4779c195-4b68-4bfb-9192-b99c63db31e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001063623033233637:f6ba0913-e0b0-4a87-9df0-aa6384e74000","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2022282168509055104:ffc4afa4-639b-4db2-8580-ff5a3869c085","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2022380980720283780:63499583-578e-4c60-ab47-a48a0358d499","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2026286387960377816:807c5ccd-d6d2-4c5f-93c0-08b72cacbab9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053043882770784323:c423092b-8f40-4eb7-8186-e09517815759","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2079956166906671286:bd5a1c32-c6f7-4658-95e3-1d1a35956949","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098565312912539987:20b585d1-821f-4e5e-a85b-13c9e9a69bdd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100223580956971178:e51546b7-3d1f-4821-8f48-3ec4cf5fdfa1","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JS8AIPtNW8A","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:K9KQ45xIKM4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:hEbZ9T0VHww","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:qIjzI4sy53k","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:uOs19N6cqAc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ujHoOcDJIsQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:xMv6anzfLfo","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":22,"publication":0,"registry":0,"regulatory":0,"x_thread":136,"x_video":0,"youtube":7},"by_evidence_role":{"commentary":165},"count":165,"evidence_window":{"end":"2026-09-16","start":"2021-11-06"},"retrieval_snapshot":"2026-10-08T04:04:08.336751Z","timeline":[{"count":1,"week":"2021-W44"},{"count":1,"week":"2023-W06"},{"count":1,"week":"2023-W13"},{"count":1,"week":"2023-W23"},{"count":1,"week":"2023-W26"},{"count":2,"week":"2023-W36"},{"count":49,"week":"2023-W37"},{"count":7,"week":"2023-W38"},{"count":2,"week":"2023-W39"},{"count":4,"week":"2023-W40"},{"count":2,"week":"2023-W41"},{"count":3,"week":"2023-W42"},{"count":5,"week":"2023-W43"},{"count":1,"week":"2023-W44"},{"count":2,"week":"2023-W45"},{"count":2,"week":"2023-W46"},{"count":1,"week":"2023-W51"},{"count":3,"week":"2024-W08"},{"count":1,"week":"2024-W09"},{"count":1,"week":"2024-W10"},{"count":1,"week":"2024-W12"},{"count":1,"week":"2024-W14"},{"count":9,"week":"2024-W16"},{"count":2,"week":"2024-W17"},{"count":1,"week":"2024-W18"},{"count":5,"week":"2024-W19"},{"count":5,"week":"2024-W20"},{"count":1,"week":"2024-W21"},{"count":2,"week":"2024-W22"},{"count":3,"week":"2024-W23"},{"count":2,"week":"2024-W25"},{"count":1,"week":"2024-W31"},{"count":2,"week":"2024-W37"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2024-W49"},{"count":4,"week":"2024-W50"},{"count":1,"week":"2024-W51"},{"count":5,"week":"2025-W02"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W10"},{"count":1,"week":"2025-W11"},{"count":3,"week":"2025-W12"},{"count":2,"week":"2025-W13"},{"count":2,"week":"2025-W14"},{"count":1,"week":"2025-W16"},{"count":1,"week":"2025-W26"},{"count":2,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W38"},{"count":1,"week":"2025-W40"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":4,"week":"2025-W44"},{"count":2,"week":"2025-W51"},{"count":2,"week":"2026-W07"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W35"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W38"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":{"reason":"Registry lists no drug interventions.","status":"not_applicable"},"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Mesothelioma","slug":"mesothelioma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"MARS2","aliases":["MARS2","Mesothelioma and Radical Surgery 2","Mesothelioma and Radical Surgery 2: a Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no (Extended) Pleurectomy Decortication for Patients With Malignant Pleural Mesothelioma (Mars 2)."],"brief_title":"Mesothelioma and Radical Surgery 2","collaborators":["University of Bristol","National Institute for Health Research, United Kingdom"],"conditions":["Mesothelioma"],"enrollment":{"count":328,"type":"ESTIMATED"},"excluded_lookalike_trials":{"reason":"No owner-reviewed lookalike exclusion list.","status":"not_set"},"interventions":[{"name":"(Extended) pleurectomy decortication","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"PROCEDURE"}],"nct_id":"NCT02040272","official_title":"Mesothelioma and Radical Surgery 2: a Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no (Extended) Pleurectomy Decortication for Patients With Malignant Pleural Mesothelioma (Mars 2).","overall_status":"UNKNOWN","phase":["NA"],"primary_completion_date":{"date":"2020-09","type":"ESTIMATED"},"primary_endpoints":[{"description":"The time from randomisation to death will be measured and date of death will be collected on purposely designed case report forms.","measure":"Survival","timeFrame":"24 months"}],"registry_last_updated":"2019-10-30","registry_url":"https://clinicaltrials.gov/study/NCT02040272","short_name":"MARS2","short_name_basis":"registry_acronym","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","start_date":{"date":"2015-05"},"study_design":"interventional, randomized, parallel, na","study_ids":[{"id":"MARS2","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}